Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it will be providing an update on its Ifenprodil idiopathic pulmonary fibrosis (IPF) and chronic cough Phase 2 human study, presented by Dr. Mark Williams, CSO and special guest panellist Dr. Martin Kolb. Dr. Martin Kolb is a leading global scientifi
VANCOUVER, British Columbia, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it will be providing an update on its Ifenprodil idiopathic pulmonary fibrosis (IPF) and chronic cough Phase 2 human study, presented by Dr. Mark Williams, CSO and special guest panellist Dr. Martin Kolb. Dr. Martin Kolb is a leading global scientific expert and clinician in the area of IPF and is the Moran Campbell Chair, Professor in Respiratory Medicine and Director of the Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
The BioPub webcast will be held Wednesday, August 26, 2020 hosted by Dr. KSS at noon EDT. The Company invites interested shareholders, investors, members of the media and the public to listen to the interview free of charge.
BioPub has been analyzing small-cap special situation biotech investments for 7 years to readers in over 40 countries.
BioPub.co Presents: Algernon Pharmaceuticals’ Phase 2 IPF and Chronic Cough Study Update
When: August 26, 2020 12:00 PM EDT
Please click the link below to join the webinar:
https://us02web.zoom.us/j/85700905505
Or iPhone one-tap :
US: +13017158592, 85700905505# or +13126266799, 85700905505#
Or Telephone:
US: +1 301 715 8592 or +1 312 626 6799 or +1 346 248 7799 or +1 646 558 8656 or +1 669 900 9128 or +1 253 215 8782
Webinar ID: 857 0090 5505
International numbers available: https://us02web.zoom.us/u/kkHi2pq1W
About BioPub
BioPub.co is a biotech investment discussion website. Our goal is to be the secret weapon and unfair advantage of every subscriber. What you will find is an education including interviews others don’t get and presence at meetings others don’t bother to attend. We promote what we consider best in class companies and follow them closely to ensure that management is executing their business plan faithfully and that development trials proceed as expected. We leverage the knowledge brought to the table by our professional members to see if the products being brought to market make sense financially in a world whose rules are changing daily.
About Algernon Pharmaceuticals Inc.
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
